ADHD is officially classified as a neurodevelopmental disorder, not a neurological disorder in the traditional sense. The distinction matters: neurological disorders like epilepsy or Parkinson’s disease involve damage to or degeneration of the nervous system, while neurodevelopmental disorders originate in how the brain develops from early life. Both the DSM-5-TR and the ICD-11, the two major diagnostic manuals used worldwide, place ADHD in the neurodevelopmental category alongside autism and intellectual disabilities.
That said, ADHD has a clear neurological dimension. Brain imaging studies reveal structural differences, chemical signaling works differently, and neural networks communicate in measurably distinct patterns. So while the formal label is “neurodevelopmental,” the condition is rooted in brain biology.
What “Neurodevelopmental” Actually Means
The DSM-5-TR defines neurodevelopmental disorders as conditions “characterized by developmental deficits or differences in brain processes that produce impairments of personal, social, academic, or occupational functioning.” The key word is “developmental.” These aren’t conditions you acquire through injury or disease later in life. They emerge as the brain is being built, shaped by genetics and early environment, and they persist into adulthood.
The classification has a complicated history. In the early 1900s, hyperactive and inattentive behavior in children was attributed to “minimal brain damage,” the assumption being that some unseen injury caused the symptoms. By the 1960s, researchers recognized that no actual damage needed to exist, and the label shifted to “minimal brain dysfunction,” emphasizing differences in how the central nervous system operated rather than proven anatomical harm. That reframing laid the groundwork for the three core symptom domains still used today: problems with attention, impulse control, and motor regulation.
One important caveat: the DSM-5-TR explicitly states that no biological marker can diagnose ADHD, and that neuroimaging cannot be used for diagnosis. The condition is still identified through behavioral criteria, patterns of inattention, hyperactivity, and impulsivity observed across multiple settings. The neurodevelopmental label reflects scientific understanding of the condition’s origins, but diagnosis remains clinical rather than scan-based.
How ADHD Brains Differ Structurally
Even though brain scans can’t diagnose ADHD in an individual, group-level studies consistently find structural differences. Research published in Molecular Psychiatry using advanced imaging correction methods found reduced brain volume in frontotemporal regions in children with ADHD, with the most significant reductions in the right middle temporal gyrus, an area involved in language processing, attention, and recognizing social cues.
Other studies have reported volume differences in the prefrontal cortex (the brain’s planning and decision-making center), the caudate nucleus and putamen (deep brain structures involved in motivation and movement), and the parietal and temporal regions. The findings aren’t always consistent in direction; some studies find certain areas larger, others smaller. But the prefrontal cortex shows up repeatedly, which makes sense given its role in the executive functions that ADHD disrupts most.
The Chemical Signaling Problem
Two brain chemicals sit at the center of ADHD: dopamine and norepinephrine. In the prefrontal cortex, these chemicals work as a team. Norepinephrine strengthens the “signal,” helping relevant information stand out, while dopamine reduces the “noise,” dampening irrelevant background activity. When either chemical is too low or too high in this region, the result looks a lot like ADHD: poor working memory, increased impulsivity, and difficulty staying on task.
Animal studies show this directly. When researchers block norepinephrine receptors in the prefrontal cortex of monkeys, the animals develop impaired working memory, increased impulsivity, and hyperactivity, essentially recreating the core symptoms of ADHD. The most effective ADHD treatments work by increasing the availability of both dopamine and norepinephrine in this same brain region, which strengthens the prefrontal cortex’s ability to regulate behavior and attention.
Neural Networks That Don’t Switch Cleanly
Your brain has a “default mode network” that activates when you’re daydreaming, mind-wandering, or not focused on any particular task. It also has “task-positive networks” that fire up when you need to pay attention or respond to something. In a typical brain, these two systems have a seesaw relationship: when one is active, the other quiets down.
In ADHD, this seesaw doesn’t work as cleanly. A large mega-analysis combining multiple research samples found that people with ADHD show weaker anticorrelation between the default mode network and several task-positive networks, including those responsible for directing attention, detecting important stimuli, and controlling movement. In practical terms, the daydreaming network doesn’t fully quiet down when the focus network needs to take over. This is consistent with the everyday ADHD experience of a wandering mind intruding during tasks that demand sustained attention. These findings held up even after accounting for other mental health conditions and medication use.
Executive Function: Where It Shows Up in Daily Life
The brain differences described above converge on a set of mental skills collectively called executive functions. Three core components are consistently impaired in ADHD: working memory (holding and manipulating information in your mind), inhibitory control (stopping yourself from acting on impulse), and set shifting (flexibly switching between tasks or mental strategies).
These aren’t abstract concepts. Working memory deficits mean losing track of multi-step instructions, forgetting what you walked into a room to do, or struggling to follow a conversation with multiple threads. Inhibitory control problems show up as blurting out answers, making impulsive purchases, or difficulty waiting your turn. Poor set shifting makes it hard to transition between activities or adapt when plans change. Downstream, these deficits create difficulties with planning, organization, maintaining goals over time, and tolerating delays, all hallmarks of ADHD that persist well beyond childhood for many people.
Genetics Account for Most of the Risk
ADHD is one of the most heritable psychiatric conditions. Twin studies estimate heritability at 77 to 88%, meaning that the vast majority of variation in ADHD risk across a population is attributable to genetic factors. That’s higher than most other mental health conditions.
The genetics are complex, though. No single gene causes ADHD. The largest genome-wide analysis to date, covering more than 20,000 cases and 35,000 controls, identified 12 specific locations in the genome associated with ADHD. The genes at these locations are involved in brain-relevant functions like neuron growth, the ability of brain connections to strengthen or weaken over time, and chemical signaling between neurons. One of the identified genes, DUSP6, directly regulates dopamine signaling. Another, MEF2C, is also associated with autism and intellectual disability, hinting at shared biological pathways across neurodevelopmental conditions.
Rare genetic variants also play a role. Studies have found that deletions affecting genes for glutamate receptors, another major brain signaling system, are significantly more common in children with ADHD than in unaffected children. Common genetic variants identified so far explain only about 22% of the heritability, leaving a large gap that likely involves rare mutations, gene interactions, and gene-environment interplay that researchers are still working to map.
How Treatment Targets Brain Chemistry
Stimulant medications reduce ADHD symptoms in roughly 70% of people who take them. They work by blocking the proteins that reabsorb dopamine and norepinephrine back into neurons after they’ve been released. In the brain’s deep reward and movement centers, these medications block 60 to 70% of dopamine reuptake. In the frontal lobes, they block 70 to 80% of norepinephrine reuptake, which also increases dopamine levels because the same transporter handles both chemicals in that region.
The net effect is more dopamine and norepinephrine available in exactly the circuits that are underperforming. Brain imaging studies show that stimulant medication increases activation in the right inferior frontal region, an area critical for impulse control, and in the putamen, a structure tied to habit formation and goal-directed movement. These aren’t corrections of a “broken” brain so much as adjustments that bring chemical signaling closer to the range where the prefrontal cortex can do its job effectively.